Cargando…
Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
INTRODUCTION: As the number of Alzheimer's disease (AD) prevention studies grows, many individuals will need to learn their genetic and/or biomarker risk for the disease to determine trial eligibility. An alternative to traditional models of genetic counseling and disclosure is needed to provid...
Autores principales: | Langlois, Carolyn M., Bradbury, Angela, Wood, Elisabeth M., Roberts, J. Scott, Kim, Scott Y.H., Riviere, Marie-Emmanuelle, Liu, Fonda, Reiman, Eric M., Tariot, Pierre N., Karlawish, Jason, Langbaum, Jessica B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944715/ https://www.ncbi.nlm.nih.gov/pubmed/31921963 http://dx.doi.org/10.1016/j.trci.2019.09.013 |
Ejemplares similares
-
APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts
por: Qian, Jing, et al.
Publicado: (2017) -
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease
por: Lopez Lopez, Cristina, et al.
Publicado: (2019) -
The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease
por: Langbaum, Jessica B., et al.
Publicado: (2020) -
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort
por: Tariot, Pierre N., et al.
Publicado: (2018) -
Brain imaging measurements of fibrillar amyloid‐β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele
por: Ghisays, Valentina, et al.
Publicado: (2020)